Drug profile · INN
calcipotriol + betamethasone dipropionate
ENSTILAR
calcipotriol + betamethasone dipropionate (ENSTILAR) is a vitamin d receptor agonist. Associated with Lacuna Pharma Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — calcipotriol + betamethasone dipropionate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
calcipotriol + betamethasone dipropionate (ENSTILAR) is a vitamin d receptor agonist. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN calcipotriol + betamethasone dipropionate
Brand ENSTILAR
Mechanism Vitamin D receptor agonist
Target Vitamin D3 receptor
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Vitamin D receptor agonist
Primary target: Vitamin D3 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is calcipotriol + betamethasone dipropionate?
calcipotriol + betamethasone dipropionate (ENSTILAR) is a vitamin d receptor agonist. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for calcipotriol + betamethasone dipropionate?
ENSTILAR is a marketed brand name for calcipotriol + betamethasone dipropionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.